NATICK, Mass., March 31 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) announced today that the Court of Appeals for the Federal Circuit issued a decision in the Company's stent litigation with Johnson and Johnson (J&J).
The Court of Appeals upheld the District Court's decision that JNJ's Bx Velocity and Cypher Stent Systems infringe Boston Scientific's patent and that the patent is valid. The Appeals Court reversed the District Court with respect to the TAXUS Liberte Stent and instructed the District Court to dismiss with prejudice the infringement claims against the TAXUS Liberte Stent.
The Court of Appeals affirmed the District Court's ruling that Boston Scientific's Express, TAXUS Express and Liberte Stents infringe one J&J patent and that the patent is valid. The Court also affirmed that Boston Scientific's Liberte Stent infringes a second J&J patent and that the patent is valid.
Damages will be determined in a future court proceeding.
"We are gratified the appeals court upheld the finding that the BX Velocity and Cypher stents infringe our patent and the patent is valid, and we are pleased the infringement claims against the TAXUS Liberte stent were dismissed with prejudice," said Jim Tobin, President and Chief Executive Officer of Boston Scientific. "We consider the outcome of this appeal to be highly positive."
Boston Scientific is a worldwide developer, manufacturer and marketer of medical devices whose products are used in a broad range of interventional medical specialties. For more information, please visit: www.bostonscientific.com.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains forward-look
|SOURCE Boston Scientific Corporation|
Copyright©2009 PR Newswire.
All rights reserved